Neprilysin inhibitor–angiotensin II receptor blocker combination (sacubitril/valsartan): rationale for adoption in SARS-CoV-2 patients

European Heart Journal - Cardiovascular Pharmacotherapy

13 April 2020
Organised by: Logo
ESC Journals

Contributors

Pietro Scicchitano
Pietro Scicchitano

Author

Murgia Hospital Fabio Perinei Altamura , Italy

ESC 365 is supported by